Odonate Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Odonate's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2021 |
Recent past performance updates
Recent updates
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Nov 18
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Jun 09Odonate Therapeutics: Lessons Learned
Apr 27We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn Rate
Mar 09Revisiting Odonate Therapeutics
Feb 01Odonate: A Simple Story Of An Oral Taxane
Jan 10Odonate Therapeutics: Likely Tesetaxel Approval Means Company Is Undervalued
Jan 08Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of Shares
Jan 07Odonate CEO buys $4.2M shares
Dec 24Odonate announces positive Phase 3 data in metastatic breast cancer
Dec 11Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?
Dec 09
Odonate Therapeutics EPS in-line
Oct 28Revenue & Expenses BreakdownBeta
How Odonate makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 21 | 0 | -102 | 9 | 71 |
| 30 Jun 21 | 0 | -119 | 11 | 97 |
| 31 Mar 21 | 0 | -130 | 10 | 120 |
| 31 Dec 20 | 0 | -126 | 10 | 117 |
| 30 Sep 20 | 0 | -122 | 11 | 113 |
| 30 Jun 20 | 0 | -118 | 11 | 110 |
| 31 Mar 20 | 0 | -113 | 11 | 105 |
| 31 Dec 19 | 0 | -112 | 11 | 104 |
| 30 Sep 19 | 0 | -113 | 11 | 105 |
| 30 Jun 19 | 0 | -110 | 11 | 102 |
| 31 Mar 19 | 0 | -101 | 11 | 92 |
| 31 Dec 18 | 0 | -89 | 11 | 80 |
| 30 Sep 18 | 0 | -76 | 11 | 66 |
| 30 Jun 18 | 0 | -62 | 9 | 54 |
| 31 Mar 18 | 0 | -47 | 7 | 40 |
| 31 Dec 17 | 0 | -33 | 5 | 28 |
| 30 Sep 17 | 0 | -19 | 2 | 17 |
| 30 Jun 17 | 0 | -10 | 1 | 8 |
| 31 Mar 17 | 0 | -6 | 1 | 5 |
| 31 Dec 16 | 0 | -3 | 0 | 3 |
Quality Earnings: Insufficient data to determine if ODTC.D has high quality earnings.
Growing Profit Margin: Insufficient data to determine if ODTC.D's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ODTC.D's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare ODTC.D's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if ODTC.D's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: ODTC.D has a negative Return on Equity (0%), as it is currently unprofitable.